ASN: Aggressive Control of BP, Lipids in T2DM May Up Kidney Risk
THURSDAY, Nov. 1, 2018 -- Intensive blood pressure (BP) control and fenofibrate use in patients with type 2 diabetes who are at high risk for cardiovascular disease may increase the risk for adverse kidney events, according to a study published in...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Fenofibrate | Heart | Pharmaceuticals | Study | Tricor | Urology & Nephrology